In this episode, UROONCO BCa chief editor Dr. Benjamin Pradere interviews Dr. Trinity Bivalacqua on the first results from CORE-008 Cohort CX- phase 2 study of intravesical cretostimogene grenadenorepvec with gemcitabine in patients with high-risk BCG-exposed or BCG-unresponsive non-muscle invasive bladder cancer. They talk in detail of the rational and results of this cohort, and the role of cretostimogene in treatments of BCG-exposed or BCG-unresponsive bladder cancer. For more ...